Preventive VT Substrate Ablation in Ischemic Heart Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Ventricular TachycardiaVentricular ArrythmiaSudden Cardiac DeathSudden Cardiac Death Due to Cardiac ArrhythmiaIschemic Heart DiseaseMyocardial InfarctionMagnetic Resonance Imaging
Interventions
PROCEDURE

Ventricular tachycardia substrate-based radiofrequency ablation

The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.

Trial Locations (1)

08022

RECRUITING

Centro Medico Teknon, Barcelona

All Listed Sponsors
lead

Centro Medico Teknon

OTHER